Tisagenlecleucel In Primary CNS Lymphoma

Status Active, not recruiting

Clinical Trial Summary

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. . -The name of the study intervention is tisagenlecleucel.

Clinical Trial Description

This research study is a Pilot Study, which is the first time investigators are examining this intervention in people with primary central nervous system lymphoma. - The name of the study intervention is tisagenlecleucel. Tisagenlecleucel is an investigational treatment that uses the participants own immune cells, called T cells, to try to kill the cancerous cells - The research study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits. - The study treatment will be one day and participants will be followed for up to 2 years. - It is expected that about 6 people will take part in this research study ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04134117
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 11, 2019
Completion date	December 11, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05036564` - Diagnosis; Objective RespOnse; THErApy	N/A
Recruiting	`NCT03569995` - [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma	Phase 2
Recruiting	`NCT04627753` - Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.	Phase 2
Recruiting	`NCT05518383` - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021	Phase 4
Recruiting	`NCT05425654` - RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL	Phase 2
Terminated	`NCT04073147` - Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma	Phase 1
Active, not recruiting	`NCT04443829` - Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma	Phase 1
Recruiting	`NCT04006561` - Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Recruiting	`NCT04656431` - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma	Phase 1
Active, not recruiting	`NCT04464200` - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers	Phase 1
Recruiting	`NCT02934204` - Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma	Phase 2
Recruiting	`NCT04947319` - Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)	Phase 2
Withdrawn	`NCT03212807` - Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL	Phase 2